We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00985738
Recruitment Status : Terminated (Low recruitment)
First Posted : September 28, 2009
Results First Posted : April 18, 2016
Last Update Posted : May 17, 2016
Information provided by (Responsible Party):
University of Colorado, Denver

Brief Summary:
The purpose of this study is to determine the effect of short-term intake of daily Dutasteride in patients with prostate cancer.

Condition or disease Intervention/treatment Phase
Prostate Cancer Drug: Dutasteride Other: Placebo Phase 2

Detailed Description:
This is a study of men who have undergone a standard 10 or more core biopsy for detection of prostate cancer and determined to have prostate cancer by having a Gleason score ≤ 7 (low to moderate risk 2-7). Of these men, one arm of a two arm randomized group will be administered a treatment regime of Dutasteride versus the control group who receive standard of care, prior to mapping biopsy. This proposal aims at studying the apparent effect of the use of Dutasteride (3 months) on initial tumor volume (at diagnosis) in men with low volume cancer before undergoing 3D mapping biopsy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 16 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized Placebo-Controlled Double-Blind Clinical Trial to Assess the Role of Dutasteride in Patients Undergoing 3D Mapping Biopsy in Early Stage Prostate Cancer
Study Start Date : September 2009
Actual Primary Completion Date : January 2013
Actual Study Completion Date : January 2013

Resource links provided by the National Library of Medicine

Drug Information available for: Dutasteride

Arm Intervention/treatment
Experimental: Dutasteride
The drug, Dutasteride, will be administered at 0.5 mg dose and given everyday (QD), for 3 months.
Drug: Dutasteride
Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
Other Name: Avodart

Placebo Comparator: Placebo
The placebo group will receive a placebo drug for 3 months, instead of the intervention drug, Dutasteride.
Other: Placebo
The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.

Primary Outcome Measures :
  1. To Determine the Effect of Short-term Intake of Daily Dutasteride Prostate Cancer Volume, Distribution Within the Gland and Gleason Score Sum in Patients in Comparison to Placebo After Adjusting for Changes in Prostate Gland Volume. [ Time Frame: 24 Months ]
    The effect of Dutasteride intake on the following parameters as detected by mapping biopsy vs. initial trans-rectal biopsy in the treatment arm and the control group: change in prostate gland volume, change in distribution within the gland, and change in Gleason score sum.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 40-85 year old males
  • Patient is newly diagnosed with clinical Stage T1a-T2c prostate cancer based on transrectal guided extended prostate biopsy of at least 10 cores.
  • Patient elects to undergo 3D mapping biopsy at our center as part of prostate cancer management.
  • Patient will read, understand and sign the informed consent agreement
  • Patients must have a life expectancy of at least one year.
  • Gleason score ≤ 7 (low to moderate risk 2-7) 7= 3+4
  • Percentage positive core rate < 50% based on sextant or extended biopsy technique.
  • Prostate Volume (PV) >15 grams.
  • Negative imaging studies ( if available) during the staging period such as Bone scan, MRI and CT scan if PSA> 10 ng.dl before initiation of the study drug

Exclusion Criteria:

  • Any 5α-reductase inhibitors medications within the past 12 months before enrollment.
  • Known hypersensitivity to dutasteride, or other 5α-reductase inhibitors.
  • Anticipated blood donation within the next 90 days.
  • Serum PSA levels of >20ng/dl.
  • Clinical evidence of metastatic prostate cancer.
  • Two documented urinary tract infections in the past year
  • CHF, MI (within 6 months) or other symptomatic CVS disease
  • Other serious diseases (hematological, hepatic, renal, respiratory or psychiatric)
  • Enrollment in other studies for any disease in the past 30 days
  • Significant urinary incontinence
  • Diagnosis of cancer that in not considered cured, except BCC of skin
  • Prior transurethral resection of the prostate with a large tissue defect.
  • History of abdominoperineal resection for rectal cancer, rectal stenosis, or other major rectal pathology
  • Previous or concurrent radiotherapy, hormonal therapy or chemotherapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00985738

Layout table for location information
United States, Colorado
University of Colorado Hospital
Aurora, Colorado, United States, 80045
Sponsors and Collaborators
University of Colorado, Denver
Layout table for investigator information
Principal Investigator: Al Barqawi, MD University of Colorado, Denver
Additional Information:
Layout table for additonal information
Responsible Party: University of Colorado, Denver
ClinicalTrials.gov Identifier: NCT00985738    
Other Study ID Numbers: 09-0247.cc
First Posted: September 28, 2009    Key Record Dates
Results First Posted: April 18, 2016
Last Update Posted: May 17, 2016
Last Verified: March 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of Colorado, Denver:
Prostate Cancer
Early Stage Prostate Cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases
5-alpha Reductase Inhibitors
Steroid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs